Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.

Transplant 40

Transplant Heart Transplant Heart Dysfunction Heart Failure 40

DAIC

MAY 15, 2024

milla1cf Wed, 05/15/2024 - 08:50 May 15, 2024 — The U.S. 882 Dates Distributed: March 1, 2021 to present Date Initiated by Firm: March 13, 2024 Device Use The HeartMate 3 Left Ventricular Assist System (LVAS) is used to help the heart pump blood when it is not able to do so effectively on its own.

Transplant 105

Transplant Heart Failure Heart Transplant Pediatrics 105

DAIC

APRIL 15, 2024

Image courtesy of Abbott mtaschetta-millane Mon, 04/15/2024 - 09:54 April 15, 2024 — The U.S. 13,883 Date Initiated by Firm: February 19, 2024 Device Use The HeartMate II and HeartMate 3 Left Ventricular Assist Systems (LVAS) are used to help the heart pump blood when it's not able to do so effectively on its own.

Transplant 105

Transplant Heart Transplant Pediatrics Heart Failure 105

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4123674-A4123674, November 12, 2024. Background:Transplantation arteriosclerosis is one of the major complications for the mid- and long-term survival of recipients with organ transplantation.

Transplant 40

Transplant Innovation Circulation 40

Cardiology Update

APRIL 9, 2024

The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. The Impella CP is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation. April 6, 2024. April 7, 2024. April 7, 2024. April 7, 2024.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

Circulation: Cardiovascular Imaging, Volume 17, Issue 1 , Page e015858, January 1, 2024. BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. years post-transplant. A minority had abnormal MPI (n=58, 15%). 2.66];P=0.33). year versus 3.6%/year

Transplant 40

Transplant Coronary Artery Disease Myocardial Infarction Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146920-A4146920, November 12, 2024. Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While

Transplant 40

Transplant Heart Transplant Risk Factors Outcomes 40

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

Circulation: Cardiovascular Imaging, Volume 17, Issue 1 , Page e016408, January 1, 2024.

Transplant 40

Transplant Cardiovascular Imaging Circulation 40

DAIC

MARCH 8, 2024

Cardiac transplantation, the only option for many patients, is severely restricted by the limited availability of donor hearts. As an alternative therapeutic option, LVAD heart pumps have been implanted to help patients with end-stage heart failure sustain blood circulation in the body. The research is funded by a four-year, $7.8

Blood Clot 98

Blood Clot Heart Failure Quality of Life Innovation 98

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5

Cardiogenic Shock 40

Cardiogenic Shock Congenital Heart Disease Heart Failure Congenital 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4113494-A4113494, November 12, 2024. End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity.

Ischemia 40

Ischemia Transplant Heart Transplant Biomarkers 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142247-A4142247, November 12, 2024. Background:Cardiac transplantation remains the single most effective treatment for end-stage heart failure. Autoradiography revealed68Ga-grazytracer accumulation in the transplanted heart. at POD 7 days; P<0.001).

Transplant 40

Transplant Heart Failure Circulation Outcomes 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page ASa1109-ASa1109, November 12, 2024. We assessed the correlates of predicted peak VO2, and the relationship between predicted peak VO2quartiles and cardiovascular outcomes (death/transplant).Results:Of 15.2 - 23.9) 1.69, p<0.001).Conclusions:The

Transplant 40

Transplant Outcomes Exercise Cardiovascular Disease 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4145296-A4145296, November 12, 2024. Aortic valve stenosis (AS) is often a contraindication to liver transplantation (LT). Aortic valve peak velocity (AVVmax) increased steadily as patients neared transplant and dropped significantly immediately after transplantation (Figure 1A).

Aortic valve 40

Aortic valve Aortic Transplant Stenosis 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144461-A4144461, November 12, 2024. Introduction:Left ventricular assist devices (LVADs) have become an increasingly common treatment option for patients with advanced heart failure, serving as either a bridge to transplantation or destination therapy.

Transplant 40

Transplant Risk Factors Heart Failure Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with heart transplant who had EMB were compared to those without heart transplant who did not have EMB p=0.001.

Cardiomyopathy 40

Cardiomyopathy Pediatrics Heart Transplant Heart Failure 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144326-A4144326, November 12, 2024. It has changed the fate of young patients with large tumors who would have otherwise needed heart transplants, offering high suture strength and reducing postoperative complications. During a median follow-up period of 17.4

Pediatrics 40

Pediatrics Outcomes Heart Transplant Aneurysm 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142203-A4142203, November 12, 2024. Background:Donation after Circulatory Death (DCD) donor hearts are rarely utilized for transplantation following more than 30 minutes of ischemia.

Ischemia 40

Ischemia Transplant Cardiac Function Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4140979-A4140979, November 12, 2024. Background:Lipid metabolic alterations are emerging as significant mechanisms in the prognosis of cardiac remodeling induced by hypertension and could impact the therapies for cardiac fibrosis.

Hypertension 40

Hypertension Transplant Cardiac Function Circulation 40

Circulation: Cardiovascular Imaging

DECEMBER 16, 2024

Circulation: Cardiovascular Imaging, Volume 17, Issue 12 , Page e016882, December 1, 2024. BACKGROUND:Right ventricular-arterial coupling (RVAC) describes the relationship between right ventricular contractility and pulmonary vascular afterload.

Pediatrics 40

Pediatrics Pulmonary Hypertension Congenital Heart Disease 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146624-A4146624, November 12, 2024. Introduction:Ventricular assist devices (VADs) present great promise as both bridge-to-transplant and destination therapies for patients with end-stage heart failure.

Thrombosis 40

Thrombosis Transplant Heart Failure Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146466-A4146466, November 12, 2024. Background:Without timely intervention, pressure-overloading left ventricular (poLV) remodeling may become progressive and readily degenerate into heart failure.

Congenital Heart Disease 40

Congenital Heart Disease Heart Failure Pediatrics Transplant 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142556-A4142556, November 12, 2024. CMR feature tracking (CMR-FT) was performed to evaluate the left ventricular (LV) global strain in all three directions.

Transplant 40

Transplant Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139383-A4139383, November 12, 2024. Background:Immunosuppressive (IS) therapy is currently used as first-line treatment for heart transplant (HTx) rejection. However, they are not without complications, and less toxic therapies are needed. years, males: 58.4%).

Heart Transplant 40

Heart Transplant Transplant Cardiovascular Disease Outcomes 40

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4138589-A4138589, November 12, 2024. All patients were prospectively followed for development of new outcome/cardiac events which included hospitalization for acute HF, CVS-related death, heart transplantation, and also diabetic complications.

Coronary Artery Disease 40

Coronary Artery Disease Diabetes Heart Transplant Tricuspid 40